Sangamo Therapeutics ran out of cash. Eli Lilly and Astellas want the science it spent decades building.

The Mission Biopharma SHAKTI scheme, launched in 2026-27, marks an important step in promoting biologics and biosimilars ...

Sangamo Therapeutics, a pioneering gene editing biotech company in the Bay Area, has filed for Chapter 11 bankruptcy protection and agreed to sell some of its programs and platforms to Eli Lilly and ...

Alamo Biologics filed for bankruptcy protection after a trade-secret lawsuit led to a multimillion-dollar collection fight.

Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for ...

While India’s pharmaceutical sector has strong foundational advantages in generic manufacturing, scale, and regulatory ...

Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five ...

Find out more about the wave of biotech rebranding and why a growing number of companies are choosing this path to start ...

Stealth BioTherapeutics is looking to put its tumultuous path behind it with a new name. | Stealth BioTherapeutics is looking ...

Sangamo Therapeutics ( (SGMO) ) has provided an update.

Of all the decisions that go into a college application, the choice of major is one of the most important yet misunderstood ...

Fermentation startups making food colors, proteins, sweeteners and specialty ingredients are attracting investment, ...